Our data supports the notion that HRR deficiency resulting from alterations in non-BRCA genes is unlikely to be of similar therapeutic relevance in comparison to BRCA2 deficiency, considering that mutations in the TP53 gene occur in more than 50% of all cancers. Here, BRCA2 is linked to cancer.